Immunology Advantage Cylex Inc. specializes in measuring immune cell function with ImmuKnow, a clinically validated in vitro diagnostic used to assess cell-mediated immunity in immunosuppressed populations, presenting a clear opportunity to expand partnerships with transplant centers and immunology research labs.

Regulatory & Quality ISO 13485:2003 and ISO 9001:2000 certifications and CMDCAS compliance signal strong quality systems, reassuring potential buyers and distributors about manufacturing reliability and regulatory readiness in global markets.

Patented moat A method patent on T-cell activation and a portfolio of patents in multiple regions create defensible technology that can be leveraged in discussions with healthcare providers, contract manufacturers, and potential licensing partners.

Global outreach With a global life science focus and centers like organ transplant programs adopting ImmuKnow, there are scalable opportunities to partner with international clinical networks, CROs, and reference laboratories for adoption and distribution.

Growth signals Recent funding visibility with enterprise revenue in the mid seven-figures range suggests readiness for expanded sales efforts, channel partnerships, and additional product introductions to broaden the immune monitoring portfolio.